Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis DOI Creative Commons
Yu Jiang, Young Goo Song, Qin Zeng

и другие.

Bioengineering, Год журнала: 2024, Номер 11(11), С. 1160 - 1160

Опубликована: Ноя. 18, 2024

Sepsis is a life-threatening disease caused by the overwhelming response to pathogen infections. Currently, treatment options for sepsis are limited broad-spectrum antibiotics and supportive care. However, growing resistance of pathogens common complicates efforts. Excessive immune (i.e., cytokine storm) can persist even after infection cleared. This overactive inflammatory severely damage multiple organ systems. Given these challenges, managing excessive critical in controlling progression. Therefore, Mesenchymal stem cells (MSCs), with their immunomodulatory antibacterial properties, have emerged as promising option adjunctive therapy treating sepsis. Moreover, MSCs exhibit favorable safety profile, they eventually eliminated host's system within several months post-administration, resulting minimal side effects not been linked antibiotic drawbacks resistance). review explores potential personalized treatment, clarifying mechanisms action providing up-to-date technological advancements enhance protective efficacy patients suffering from its consequences.

Язык: Английский

Nanoparticles of Natural Product-derived Medicines: Beyond the Pandemic DOI Creative Commons
Yedi Herdiana

Heliyon, Год журнала: 2025, Номер 11(4), С. e42739 - e42739

Опубликована: Фев. 1, 2025

This review explores the synergistic potential of natural products and nanotechnology for viral infections, highlighting key antiviral, immunomodulatory, antioxidant properties to combat pandemics caused by highly infectious viruses. These often result in severe public health crises, particularly affecting vulnerable populations due respiratory complications increased mortality rates. A cytokine storm is initiated when an overload pro-inflammatory cytokines chemokines released, leading a systemic inflammatory response. Viral mutations limited availability effective drugs, vaccines, therapies contribute continuous transmission virus. The coronavirus disease-19 (COVID-19) pandemic has sparked renewed interest product-derived antivirals. efficacy traditional medicines against infections examined. Their anti-inflammatory, are highlighted. discusses how enhances herbal combating infections.

Язык: Английский

Процитировано

1

AICpred: Machine Learning-Based Prediction of Potential Anti-Inflammatory Compounds Targeting TLR4-MyD88 Binding Mechanism DOI Creative Commons

Lucindah N. Fry-Nartey,

Cyril Akafia,

Ursula S. Nkonu

и другие.

Information, Год журнала: 2025, Номер 16(1), С. 34 - 34

Опубликована: Янв. 7, 2025

Toll-like receptor 4 (TLR4) has been implicated in the production of uncontrolled inflammation within body, known as cytokine storm. Studies that employ machine learning (ML) prediction potential inhibitors TLR4 are limited. This study introduces AICpred, a robust, free, user-friendly, and easily accessible learning-based web application for predicting against by targeting TLR4-myeloid differentiation primary response 88 (MyD88) interaction. MyD88 is crucial adaptor protein TLR4-induced hyper-inflammation pathway. Predictive models were trained using random forest, adaptive boosting (AdaBoost), eXtreme gradient (XGBoost), k-nearest neighbours (KNN), decision tree models. To handle imbalance training data, resampling techniques such under-sampling, synthetic minority oversampling technique, selection 5000 instances majority class employed. A 10-fold cross-validation strategy was used to evaluate model performance based on metrics including accuracy, balanced recall. The XGBoost demonstrated superior with recall scores 0.994, 0.958, 0.917, respectively, test. AdaBoost also excelled accuracies ranging from 0.981 0.992, between 0.921 0.944, 0.845 0.891 both test datasets. deployed AICpred screen compounds have reported positive effects mitigating hyperinflammation-associated storm, which key factor COVID-19. predicted Baricitinib, Ibrutinib, Nezulcitinib, MCC950, Acalabrutinib anti-TLR4 probability above 0.90. Additionally, inhibit TLR4, TAK-242 (Resatorvid) benzisothiazole derivative (M62812), bioactive agents applicability domain probabilities 0.80. Computationally inferred can be explored starting skeletons therapeutic hyperinflammation. These predictions must consolidated experimental screening enhance further optimisation compounds. first its kind inhibition TLR4-MyD88 binding freely available at http://197.255.126.13:8080.

Язык: Английский

Процитировано

0

Immunological Disorders: Gradations and the Current Approach in Laboratory Diagnostics DOI Creative Commons
Анна Старшинова, А. А. Савченко, А. Г. Борисов

и другие.

Pathophysiology, Год журнала: 2025, Номер 32(2), С. 17 - 17

Опубликована: Апрель 18, 2025

Currently, understanding the immune response, its abnormalities, and diagnostic possibilities is a key point in management of patients with various diseases, from infectious to oncological ones. The aim this review was analyze data presented current literature on disorders possibility their laboratory diagnostics combination clinical manifestations. We have performed systematic analysis international databases over last ten years. diagnosing immunopathological processes due changes cells soluble molecules involved pathogenesis wide range as well determination antibodies detect autoimmune processes. By applying techniques such hematology, flow cytometry, ELISA, etc., available most laboratories worldwide, system dysfunction diseases are being collected. This process unfortunately still very far completed. However, all diversity accumulated knowledge, we can currently state that vast majority immune-mediated not yet known. At same time, success dividing into distinct clusters based different types inflammatory responses involvement populations T helper cytokine represents significant progress. Further research direction seems promising, it allows identification new target for both improved targeted therapies.

Язык: Английский

Процитировано

0

Role of Flavonoids in Sepsis: Advances and Future Prospects DOI Open Access

Sara Osman Esmail,

Ahmed Zorin Sahlan

Опубликована: Май 20, 2024

Due to the host immunological disease brought on by infection is sepsis, multiple organ dysfunction syndrome (MODS), which has a high morbidity and mortality rate, could be result. With advances in pathogen detection technologies, breakthroughs anti-infection drugs, creation of function support, clinical diagnosis treatment sepsis have advanced significantly. Pathogen-induced abnormal responses, can range from excessive inflammation immunosuppression, are recognized play significant role death rate. Unfortunately, no medications that specifically intended treat been licensed. In order offer theoretical foundation for management we will now discuss current advancements research responses sepsis. The prognosis patients may improved developing optimizing dynamic immune system plan based therapy, fluid replacement, support function, timely application immunomodulatory therapies

Язык: Английский

Процитировано

1

Clostridium ramosum alone caused Fournier's gangrene in an older Chinese patient with abnormal interleukin levels: A rare case report DOI Creative Commons
Hongjian Ji, Wei Shen, Xiaohua Zhou

и другие.

Heliyon, Год журнала: 2024, Номер 10(12), С. e33244 - e33244

Опубликована: Июнь 1, 2024

is an uncommon Clostridium but one of the essential anaerobic bacteria that makes up intestinal microbiota. A highly variable body temperature, white blood cell count, or elusory prognosis can reflect

Язык: Английский

Процитировано

0

Mesenchymal Stem Cells and Their Extracellular Vesicles Are a Promising Alternative to Antibiotics for Treating Sepsis DOI Creative Commons
Yu Jiang, Young Goo Song, Qin Zeng

и другие.

Bioengineering, Год журнала: 2024, Номер 11(11), С. 1160 - 1160

Опубликована: Ноя. 18, 2024

Sepsis is a life-threatening disease caused by the overwhelming response to pathogen infections. Currently, treatment options for sepsis are limited broad-spectrum antibiotics and supportive care. However, growing resistance of pathogens common complicates efforts. Excessive immune (i.e., cytokine storm) can persist even after infection cleared. This overactive inflammatory severely damage multiple organ systems. Given these challenges, managing excessive critical in controlling progression. Therefore, Mesenchymal stem cells (MSCs), with their immunomodulatory antibacterial properties, have emerged as promising option adjunctive therapy treating sepsis. Moreover, MSCs exhibit favorable safety profile, they eventually eliminated host's system within several months post-administration, resulting minimal side effects not been linked antibiotic drawbacks resistance). review explores potential personalized treatment, clarifying mechanisms action providing up-to-date technological advancements enhance protective efficacy patients suffering from its consequences.

Язык: Английский

Процитировано

0